#1 Clinical Trials Search in Europe

Bifikafusp Alfa

This article summarizes several clinical trials investigating the use of Bifikafusp Alfa, also known as L19IL2 or Darleukin, for treating different types of skin cancers. These trials are exploring the drug’s effectiveness when injected directly into tumors, either alone or in combination with other treatments. The studies focus on patients with advanced melanoma, basal cell carcinoma, squamous cell carcinoma, and other skin cancers that are difficult to treat with standard methods.

Table of Contents

What is Bifikafusp Alfa?

Bifikafusp alfa, also known as L19IL2 or Darleukin, is an innovative drug being studied for the treatment of various skin cancers[1]. It is a fusion protein that combines two important components: a targeting antibody (L19) and an immune-stimulating molecule (interleukin-2 or IL2).

How Does It Work?

Bifikafusp alfa works by targeting cancer cells and stimulating the immune system to fight them. The L19 antibody part of the drug seeks out and attaches to proteins found in tumor blood vessels. Once attached, the IL2 part activates immune cells in the area, helping them to recognize and attack the cancer cells[2].

What Conditions Does It Treat?

Bifikafusp alfa is being studied for the treatment of several types of skin cancers, including:

  • Melanoma: A serious type of skin cancer that develops in cells that produce melanin[1]
  • Basal Cell Carcinoma (BCC): The most common type of skin cancer[3]
  • Cutaneous Squamous Cell Carcinoma (cSCC): The second most common type of skin cancer[3]
  • Merkel Cell Carcinoma (MCC): A rare but aggressive type of skin cancer[4]
  • Keratoacanthoma (KA): A low-grade skin tumor that can resemble squamous cell carcinoma[4]
  • Malignant Adnexal Tumors of the Skin (MATS): Rare tumors that develop from skin appendages[4]
  • Cutaneous T-cell Lymphoma (CTCL): A type of cancer that begins in T-cells in the skin[4]
  • Kaposi’s Sarcoma (KS): A cancer that causes patches of abnormal tissue to grow under the skin[4]

How is It Administered?

Bifikafusp alfa is administered through intratumoral injection. This means the drug is injected directly into the tumor or skin lesion[1]. This method allows for targeted delivery of the medication to the cancer site.

Current Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness of bifikafusp alfa:

  1. A Phase 3 study for patients with stage IIIB/C melanoma, comparing bifikafusp alfa treatment followed by surgery to surgery alone[1].
  2. A Phase 2 study for patients with non-melanoma skin cancers, including BCC, cSCC, MCC, KA, MATS, CTCL, and KS[4].
  3. A Phase 2 study specifically for patients with high-risk, locally advanced BCC or cSCC[3].

Potential Benefits

The potential benefits of bifikafusp alfa treatment include:

  • Improved recurrence-free survival (time without cancer coming back after treatment)[1]
  • Increased overall survival (length of time patients live after diagnosis)[1]
  • Possibility of avoiding difficult or disfiguring surgeries[4]
  • Potential to make inoperable tumors operable[4]
  • Option for patients who have not responded to other treatments[3]

Possible Side Effects

As with any medical treatment, bifikafusp alfa may cause side effects. While specific side effects are still being studied in clinical trials, patients should be aware of potential risks and discuss them with their healthcare provider. Common side effects of immunotherapy drugs may include fatigue, skin reactions, and flu-like symptoms[5].

Who is Eligible for Treatment?

Eligibility for bifikafusp alfa treatment varies depending on the specific clinical trial and type of cancer. Generally, patients must:

  • Be 18 years or older[1]
  • Have a confirmed diagnosis of one of the studied skin cancers[3]
  • Have tumors that can be injected directly[4]
  • Meet specific health criteria, such as adequate organ function and performance status[1]

Patients with certain conditions, such as active autoimmune diseases, severe infections, or recent major surgeries, may not be eligible for treatment[4].

Conclusion

Bifikafusp alfa (L19IL2) represents a promising new approach in the treatment of various skin cancers. By combining targeted delivery with immune system stimulation, it offers hope for patients who may have limited treatment options. As clinical trials progress, more information will become available about its effectiveness and safety profile. Patients interested in this treatment should discuss their options with their healthcare provider and consider participating in clinical trials if eligible.

Trial Name Cancer Types Main Objective Key Eligibility Criteria
PH-L19IL2TNF-01/18 Stage IIIB/C Melanoma Improve recurrence-free survival with Bifikafusp Alfa + surgery vs. standard care Stage IIIB/C melanoma, injectable lesions, age ≥18
PH-L19IL2TNF-02/15 Stage III B/C Melanoma Improve recurrence-free survival with Bifikafusp Alfa + surgery vs. surgery alone Stage III B/C melanoma, injectable lesions, age ≥18
PHL19IL2TNFNMSC04/19 BCC, cSCC, MCC, KA, MATS, CTCL, KS Assess response rate for each tumor type using RECIST criteria Various skin cancers, injectable lesions, age ≥18
Unnamed Phase II study BCC, cSCC Evaluate response rate in high-risk, locally advanced skin cancers BCC or cSCC not eligible for standard treatments, age 18-100

FAQ

  • What is Bifikafusp Alfa? Bifikafusp Alfa, also known as L19IL2 or Darleukin, is an experimental drug being studied for treating various types of skin cancers. It is designed to be injected directly into tumors.
  • What types of skin cancers are being studied with Bifikafusp Alfa? The clinical trials are investigating Bifikafusp Alfa for advanced melanoma, basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin cancers.
  • How is Bifikafusp Alfa administered in these trials? Bifikafusp Alfa is administered through intratumoral injection, meaning it is injected directly into the tumor.
  • What are the main goals of these clinical trials? The main goals are to assess the effectiveness of Bifikafusp Alfa in shrinking tumors, improving survival rates, and evaluating its safety when used alone or in combination with other treatments like surgery.
  • Who might be eligible for these clinical trials? Eligibility varies by trial, but generally includes adult patients with advanced skin cancers that are difficult to treat with standard methods. Specific health criteria and prior treatment history also factor into eligibility.

Ongoing Clinical Trials on Bifikafusp Alfa

  • A study of onfekafusp alfa and bifikafusp alfa injected into tumors for patients with advanced skin squamous cell cancer who did not respond to or could not tolerate previous treatment

    Recruiting

    2 1 1
    Investigated drugs:
    Germany Greece Italy Spain

  • Testing bifikafusp alfa and onfekafusp alfa injections in patients with locally advanced basal cell carcinoma

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Greece Italy Spain

  • Study of bifikafusp alfa and onfekafusp alfa injected into tumors for patients with locally advanced basal cell carcinoma who progressed on or cannot tolerate systemic treatment

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Greece Italy Spain

  • Testing bifikafusp alfa, onfekafusp alfa, and pembrolizumab combination in patients with advanced melanoma that did not respond to previous immunotherapy

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany Italy

  • Study on the Effectiveness of L19IL2 and L19TNF Injections with Surgery for Patients with Stage IIIB/C Melanoma

    Recruiting

    3 1 1
    Investigated drugs:
    Germany Italy Spain Sweden

  • Study on L19IL2 and L19TNF Treatment Before Surgery for Patients with Advanced Melanoma

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland

  • Study of L19IL2 and L19TNF for Patients with Advanced Basal Cell Carcinoma or Cutaneous Squamous Cell Carcinoma Not Eligible for Surgery or Radiation

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland

  • Study of L19IL2 and L19TNF for Patients with Skin Cancer Suitable for Direct Tumor Injection

    Not recruiting

    2 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • Bifikafusp Alfa: An experimental drug also known as L19IL2 or Darleukin, being studied for treating various types of skin cancers through direct injection into tumors.
  • Intratumoral injection: A method of administering medication by injecting it directly into a tumor.
  • Melanoma: A serious type of skin cancer that develops in cells that produce melanin, the pigment that gives skin its color.
  • Basal cell carcinoma (BCC): The most common type of skin cancer, which usually develops on areas exposed to the sun.
  • Cutaneous squamous cell carcinoma (cSCC): The second most common type of skin cancer, developing in the squamous cells of the skin's outer layer.
  • Merkel cell carcinoma (MCC): A rare but aggressive type of skin cancer that usually appears as a flesh-colored or bluish-red nodule on the skin.
  • Keratoacanthoma (KA): A relatively common low-grade skin tumor that typically appears as a dome-shaped bump on sun-exposed skin.
  • Recurrence-free survival (RFS): The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Neoadjuvant treatment: Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-l19il2-and-l19tnf-injections-with-surgery-for-patients-with-stage-iiib-c-melanoma/
  2. http://clinicaltrials.eu/trial/study-on-l19il2-and-l19tnf-treatment-before-surgery-for-patients-with-advanced-melanoma/
  3. http://clinicaltrials.eu/trial/study-of-l19il2-and-l19tnf-for-patients-with-advanced-basal-cell-carcinoma-or-cutaneous-squamous-cell-carcinoma-not-eligible-for-surgery-or-radiation/
  4. http://clinicaltrials.eu/trial/study-of-l19il2-and-l19tnf-for-patients-with-skin-cancer-suitable-for-direct-tumor-injection/
  5. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects